Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.1600
Nov 20 • 3:59 PM ET Dollar change-0.0086 Percentage change(-5.10%)
Aftermarket Close
0.1600
Aftermarket • 6:42 PM ET Dollar change0.0000 Percentage change(0.00%)
Index
RUT
Market Cap
14.70M
Enterprise Value
-19.50M
Income
-43.89M
Sales
0.00M
Book/sh
0.34
Cash/sh
0.37
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
15
IPO
Oct 20, 2021
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
0.47
P/C
0.43
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
6.56
Current Ratio
6.56
Debt/Eq
0.01
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-0.47
EPS next Y
-0.38
EPS next Q
-0.09
EPS this Y
-13.23%
EPS next Y
11.78%
EPS next 5Y
-6.79%
EPS past 3/5Y
25.81% -
Sales past 3/5Y
- -
EPS Y/Y TTM
-66.49%
Sales Y/Y TTM
-
EPS Q/Q
21.32%
Sales Q/Q
-
Insider Own
17.17%
Insider Trans
0.00%
Inst Own
57.63%
Inst Trans
-8.71%
ROA
-75.82%
ROE
-84.26%
ROIC
-141.41%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-17.35%
SMA50
-39.55%
SMA200
-87.84%
Trades
Shs Outstand
91.88M
Shs Float
76.10M
52W High
3.62 -95.58%
52W Low
0.15 4.85%
Volatility
15.28% 11.65%
ATR (14)
0.02
RSI (14)
31.74
Beta
1.80
Rel Volume
0.77
Avg Volume
1.44M
Volume
1,107,287
Perf Week
-11.50%
Perf Month
-32.09%
Perf Quarter
-65.62%
Perf Half Y
-93.85%
Perf YTD
-89.12%
Perf Year
-85.96%
Perf 3Y
-82.98%
Perf 5Y
-96.73%
Perf 10Y
-
Prev Close
0.17
Price
0.16
Change %
-5.10%
Consensus
Strong Buy
Avg. Price Target
$3.50
Implied Upside
+2,087.5%
Analysts5incl. previous ratings
Rating Distribution5 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 18, 2025Initiated
GGuggenheim
Buy$5+3,025.0%
Apr 21, 2025Initiated
WWilliam Blair
Outperform
Jan 08, 2025Initiated
JJMP Securities
Mkt Outperform$4+2,400.0%
Nov 25, 2024Initiated
DD. Boral Capital
Buy$9+5,525.0%
May 16, 2024Initiated
PPiper Sandler
Overweight$4.50+2,712.5%
Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.
Co-FounderMr. Martin A. Lehr
CFO & TreasurerMs. Jennifer Minai-Azary
J.D.Mr. Alex C. Levit Esq.
Senior Vice President of OperationsMr. Christopher Beck M.B.A.
Associate Director of AccountingMr. Jeffrey Liebman